News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Advances clinical research capabilities with leading regulatory grade registries platform
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Subscribe To Our Newsletter & Stay Updated
